Unknown

Dataset Information

0

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.


ABSTRACT: Polo-like kinase 1 (Plk1) has an important role in mitosis. Volasertib (BI 6727), a potent and selective cell cycle kinase inhibitor, induces mitotic arrest and apoptosis by targeting Plk; this phase I study sought to determine its maximum tolerated dose (MTD) in Asian patients with advanced solid tumours.Patients were enrolled simultaneously into two 3-week schedules of volasertib: a 2-h infusion on day 1 (schedule A) or days 1 and 8 (schedule B). Dose escalation followed a 3+3 design. The MTD was determined based on dose-limiting toxicities (DLT) in the first treatment course.Among 59 treated patients, the most common first course DLTs were reversible thrombocytopenia, neutropenia and febrile neutropenia; MTDs were 300 mg for schedule A and 150 mg for schedule B. Volasertib exhibited multi-exponential pharmacokinetics (PK), a long terminal half-life of ∼135 h, a large volume of distribution (>3000 l), and a moderate clearance. Partial responses were observed in two pre-treated patients (ureteral cancer; melanoma). Volasertib was generally well tolerated, with an adverse event profile consistent with its antimitotic mode of action and a favourable PK profile.These data support further development of volasertib and a harmonised dosing for Asian and Caucasian patients.

SUBMITTER: Lin CC 

PROVIDER: S-EPMC4021529 | biostudies-other | 2014 May

REPOSITORIES: biostudies-other

Similar Datasets

2023-02-15 | GSE213797 | GEO
| S-EPMC5080318 | biostudies-literature
| S-EPMC6407740 | biostudies-literature
| S-EPMC8595891 | biostudies-literature
2021-08-20 | GSE174765 | GEO
| S-EPMC2844945 | biostudies-literature
| S-EPMC8766914 | biostudies-literature
| S-EPMC5199138 | biostudies-literature
| S-EPMC4387274 | biostudies-literature
| S-EPMC7825275 | biostudies-literature